Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Fibrosis, Inflammation, and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for Periostin/POSTN drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | POSTN Recombinant Protein (Isoform 1/2/4) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View POSTN Products |
| Gene Delivery | POSTN Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression assays. |
View POSTN Products |
| Benchmark Ab | Anti-POSTN Recombinant Antibody Recombinant positive control matching clinical-stage reference sequences. |
View POSTN Products |
| Validator | POSTN siRNA Set For target knockdown and specificity verification in phenotypic assays. |
View POSTN Products |
| Related Target A | Integrin alpha V beta 3 (ITGAV/ITGB3) Primary functional receptor for Periostin mediating cell adhesion and migration. |
View ITGAV Products |
| Related Target B | TGF-beta 1 (TGFB1) Upstream master regulator driving Periostin expression in fibrotic and tumor tissues. |
View TGFB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform-Specific Targeting (Splice Variants) | Sequence-verified recombinant POSTN isoforms (Isoform 1 vs. Isoform 4) to confirm antibody epitope specificity. |
| Integrin Binding Activity Verification | HEK293-expressed POSTN with native post-translational modifications (glycosylation) to preserve integrin-binding conformation. |
| Cross-species Cyno/Mouse Evaluation | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity verified by SDS-PAGE. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization. |
| False Positives | Validated siRNA included for specificity checks in cell-based assays. |
Live Periostin/POSTN R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Periostin/POSTN therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies (mAbs) to antibody-drug conjugates (ADCs) and bispecific constructs targeting the tumor microenvironment (TME). Periostin, a secreted extracellular matrix (ECM) protein, is highly upregulated in collagen-rich fibrotic tissues and stromal compartments of solid tumors. As first-generation therapies targeting tissue remodeling and type 2 inflammation (e.g., in asthma and atopic dermatitis) reach clinical evaluation, the next wave of R&D is targeting stromal-depleting strategies in oncology and severe organ fibrosis (IPF, NASH).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | AnaptysBio, Novartis, Shino-Test | Atopic Dermatitis, Asthma, Idiopathic Pulmonary Fibrosis (IPF) | Ligand-blocking assays (Need highly pure, native-conformation POSTN to block Integrin interactions) |
| Antibody-Drug Conjugate (ADC) | Preclinical stage developers | Solid Tumors (Stroma-targeting) | Internalization Assay (Need high-purity ECD-Fc for target-mediated endocytosis screening) |
| Small Molecule / Peptide Inhibitor | Academic spin-offs, Biotech | Myocardial Infarction, Osteoarthritis | High-throughput screening (HTS) binding assays (Need batch-to-batch consistent recombinant protein) |